PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
Globe Newswire•22/09/2026•08:00 ET
0
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients
Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101
Get started
Create a free account to read the full story and Whiz Insights.